Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05669326
Other study ID # 2021-A02074-37
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date February 1, 2024

Study information

Verified date December 2022
Source GCS Ramsay Santé pour l'Enseignement et la Recherche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate to what extent the capacity of the NODDI model can allow, in case of Malignant brain tumor patients with vasogenic edema, the elaboration of a reliable cerebral functional mapping in accordance with the data of direct electrical stimulation (DES) which is today the reference tool. the patient's participation in this study implies an additional visit during which an MRI examination without injection of contrast medium will be performed, lasting approximately 40 minutes (including installation and de-installation).


Description:

This is a single-center, prospective, open-label study of neurosurgical patients. Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without injection of contrast product will be performed, lasting approximately 40 minutes (including installation and de-installation). The operative time, surgical procedures and postoperative follow-up are not modified in this study


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 12
Est. completion date February 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient 18 years of age or older, - Patient who has read and signed the consent form for participation in the study - Patient requiring surgery for a malignant brain tumor with vasogenic edema - Patient with an estimated life expectancy of more than 3 months. Exclusion Criteria: - Patient under legal protection, guardianship or trusteeship - Patient not affiliated to the French social security system - Contraindication to MRI (patient with a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, patient with hemostatic clips on intracerebral aneurysms or with orthopedic implants, claustrophobic patient) - Psychiatric history - Refusal to be informed of an abnormality detected during the MRI - Pregnant or breastfeeding woman

Study Design


Related Conditions & MeSH terms


Intervention

Other:
NODDI TRACT
Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation). The operative time, surgical procedures and postoperative follow-up are not modified in this study.

Locations

Country Name City State
France Clinique de l'Union Saint-Jean

Sponsors (1)

Lead Sponsor Collaborator
GCS Ramsay Santé pour l'Enseignement et la Recherche

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response to electrical stimulation Response to electrical stimulation, which determines the presence or absence of an essential bundle, is the primary end point.
The ability of the NODDI-tract method to reconstruct essential bundles in vasogenic edema will be assessed by estimating the correspondence between the response to intraoperative direct electrical stimulation (DES) and the presence of an MRI reconstructed bundle.
Based on the response to electrical stimulation, the NODDI-tract data will be classified into one of four groups:
True positive = response to stimulation and presence of an MRI beam
True negative = no response to stimulation and no beam on MRI
False positive = no response to stimulation and presence of a beam on MRI
False-negative = response to stimulation and absence of beam in MRI. The distance between the reconstructed beam and the stimulation point (whether or not the stimulation was effective) will also be measured.
Hour 24
Secondary Number of reconstructed fibers Reconstructions obtained using the NODDI protocol or tractography will be compared on the total number of fibers reconstructed by both methods.
The comparison will be made on the total number of reconstructed fibers and on the number of reconstructed fibers crossing the edema.
Hour 24
Secondary Average distance to a reference atlas The comparison is based on the evaluation of the average distance between the skeleton of the NODDI-tract reconstructed beams and that of the JHU tractography atlas [20]. The distance will be calculated by projecting the reconstructed skeleton onto the atlas skeleton, and as a function of the length traveled on the parameterized curve representing the skeleton. This function will be averaged over the entire length of the skeleton. An average distance of less than 1cm will be considered as a match criterion. Hour 24
See also
  Status Clinical Trial Phase
Completed NCT04109209 - Psychological Intervention For Brain Tumor Caregivers N/A
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Completed NCT04351035 - National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry
Completed NCT02502708 - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Phase 1
Recruiting NCT05976490 - NeuroPathways Intervention for Brain Tumor Patients N/A
Terminated NCT02128373 - A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer N/A
Terminated NCT02885324 - Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children Phase 2
Not yet recruiting NCT06099743 - ASCENT Intervention for Brain Tumor Patients N/A
Terminated NCT02880111 - Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa
Completed NCT02052648 - Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Phase 1/Phase 2
Not yet recruiting NCT06098248 - cCeLL - Ex Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis N/A
Completed NCT00418327 - Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma Phase 1
Recruiting NCT05293197 - Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients Phase 1
Recruiting NCT06092125 - Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1